Abstract:5688 CRM1 is an essential protein required to export a set of ‘cargo’ proteins which bear a leucine-rich nuclear export sequence (NES) from the nucleus to the cytoplasm. Examples of cancer-related proteins bearing CRM1-dependent NESs include p53, BCR-Abl, and FOXO-3a. Nuclear sequestration of these CRM1 ‘cargo’ proteins upon inhibition of CRM1 can lead to cell growth inhibition in normal cells or apoptosis in cancer cells. The identification of CRM1 as a novel target in cancer came from the study of Leptomycin B (LMB) and its analogs. These molecules are potent cytotoxic agents which belong to a group of polyketide natural products known as nuclear export inhibitors (NEIs). LMB and its analogs covalently bind to the nuclear exportin CRM1 and thereby inhibit its ability to shuttle cargo proteins to the cytoplasm. The development of LMB was limited by the significant toxicity observed in previous studies (Newlands, et al., 1996, Br. J. Can., 74: 648-649). We have recently developed a series of NEI analogs with significantly improved biological and pharmacological properties over LMB. Upon examination of the activity of these molecules in leukemia cell lines, we found that NEIs were very potent in vitro in ALL (Molt-4, CCRF-CEM, Jurkat) and AML (MV-4-11) cell lines. Exposure to NEIs led to a rapid and dramatic induction of multiple markers of apoptosis (caspases, Annexin V binding). Based on these results, we examined the activity of two NEI analogs, KOS-1815 and KOS-2464, in murine leukemia xenograft models. Both of these drugs, when dosed on a weekly schedule, significantly inhibited the growth of MV-4-11 (T/C = ~22% for KOS-2464 and ~26% for KOS-1815) and Molt-4 (T/C = ~38% for KOS-2464 and ~29% for KOS-1815) xenografts. In addition, a single administration of KOS-2464 or KOS-1815 induced regression of large (>1000 mm3) CCRF-CEM xenografts. KOS-2464 was very well-tolerated at efficacious doses in all of these leukemia models, while KOS-1815 induced a ~5 to 10% transient body weight loss upon dosing. Finally, we established a Molt-4 orthotopic leukemia model in mice. Weekly dosing of KOS-1815 and KOS-2464 for three weeks, beginning eight days after cancer cell implantation, doubled survival of these leukemic mice. Median survival increased from 25 days for the control group to 50+ days for the drug-treated groups (56 days for KOS-2464 and 50 days for KOS-1815). Studies are ongoing to gain further insight into the mechanism by which these molecules exert their activity in leukemia models. Taken together, the current study shows that KOS-2464, our lead NEI analog, with its novel mechanism of action and wide therapeutic window, has significant potential as a novel anti-cancer agent, especially for the treatment of leukemia.

Pharmacodynamic and Toxicity Studies of 6-Isopropyldithio-2′-Guanosine Analogs in Acute T-Lymphoblastic Leukemia

PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

6-Dithio-2'-deoxyguanosine Analogs Induce Reactive Oxygen Species-Mediated Tumor Cell Apoptosis Via Bi-Targeting Thioredoxin 1 and Telomerase.

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

Synthesis and mechanistic studies of novel spin-labeled combretastatin derivatives as potential antineoplastic agents.

A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas

BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia

Design, synthesis and pharmacological characterization of N-(3-ethylbenzo[d]isoxazol-5-yl) sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia

Synthesis of (1,3,4-thiadiazol-2-yl)-acrylamide derivatives as potential antitumor agents against acute leukemia cells.

Design, synthesis, and pharmacological evaluation of novel benzothiazole derivatives targeting LCK in acute lymphoblastic leukemia

Synthesis, design, and antiproliferative evaluation of 6-(N-Substituted-methyl)pyrazolo[3,4-d]pyrimidines as the potent anti-leukemia agents

Design and synthesis of various quinizarin derivatives as potential anticancer agents in acute T lymphoblastic leukemia

Synthesis and Antileukemia Activity Evaluation of Benzophenanthridine Alkaloid Derivatives

Lead Optimization of Small Molecule ENL YEATS Inhibitors to Enable In Vivo Studies: Discovery of TDI-11055

Anti-tumor Activity of Novel Nuclear Export Inhibitors (neis) in Multiple Murine Leukemia Models

Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities.

Design, semi-synthesis and examination of new gypsogenin derivatives against leukemia via Abl tyrosine kinase inhibition and apoptosis induction

Design, synthesis, and biological evaluation of adenosine derivatives targeting DOT1L and HAT as anti-leukemia agents

Design, Synthesis, and Anti-Leukemic Evaluation of a Series of Dianilinopyrimidines by Regulating the Ras/Raf/MEK/ERK and STAT3/c-Myc Pathways

Design and Synthesis of 7-Azaindole Derivatives As Potent CDK8 Inhibitors for the Treatment of Acute Myeloid Leukemia

Synthesis, Assessment of Antineoplastic Activity, and Molecular Docking of Novel 2-Thioxo-oxazolidin-4-one Derivatives